RMTI vs. ARAY, RSLS, ABT, ISRG, BSX, SYK, MDT, BDX, EW, and IDXX
Should you be buying Rockwell Medical stock or one of its competitors? The main competitors of Rockwell Medical include Accuray (ARAY), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and IDEXX Laboratories (IDXX). These companies are all part of the "health care equipment" industry.
Rockwell Medical vs.
Rockwell Medical (NASDAQ:RMTI) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.
In the previous week, Accuray had 4 more articles in the media than Rockwell Medical. MarketBeat recorded 6 mentions for Accuray and 2 mentions for Rockwell Medical. Rockwell Medical's average media sentiment score of 0.00 beat Accuray's score of -0.16 indicating that Rockwell Medical is being referred to more favorably in the media.
Accuray has a net margin of -0.96% compared to Rockwell Medical's net margin of -1.25%. Rockwell Medical's return on equity of 8.55% beat Accuray's return on equity.
Rockwell Medical presently has a consensus price target of $6.00, suggesting a potential upside of 238.98%. Given Rockwell Medical's stronger consensus rating and higher possible upside, research analysts clearly believe Rockwell Medical is more favorable than Accuray.
Rockwell Medical has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Accuray has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.
23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 1.9% of Rockwell Medical shares are owned by company insiders. Comparatively, 4.2% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Rockwell Medical has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Rockwell Medical, indicating that it is currently the more affordable of the two stocks.
Accuray received 22 more outperform votes than Rockwell Medical when rated by MarketBeat users. Likewise, 65.55% of users gave Accuray an outperform vote while only 57.70% of users gave Rockwell Medical an outperform vote.
Summary
Rockwell Medical beats Accuray on 10 of the 18 factors compared between the two stocks.
Get Rockwell Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMTI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rockwell Medical Competitors List
Related Companies and Tools
This page (NASDAQ:RMTI) was last updated on 2/22/2025 by MarketBeat.com Staff
